Under the leadership of the U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr. and the U.S.

The FDA will select at most five companies that align with national priorities, including lower drug prices and increased ...

The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency.

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

FDA Commissioner Marty Makary, M.D., has made his pick for the next director of the FDA’s Center for Drug Evaluation and ...

Dr. Jacqueline Corrigan-Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, internally announced her retirement Monday.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

President Trump often touted during his first term that his administration had “approved more affordable generic drugs than any administration in history.” He had good reason to highlight ...

Expect the FDA to double-down on evidence-based decisions and clear communication of risks/benefits, as this leadership views public trust as essential for biotech innovations to succeed.